Live
- MLA Mekapati Vikram Reddy express confidence in YSRCP coming back to power
- TDP MP Candidate Kesineni Chinni says Sujana's Victory as Turning Point for West Development
- AP has seen a rapid development in YSRCP regime, says YS Jagan
- Plans Underway to Bring IT Companies to Gannavaram, Assures Yarlagadda Venkatarao's Wife Gnaneshwari
- TDP Candidate Vasantha Krishna Prasad Begins Election Campaign in Mylavaram Constituency
- Chaitra Navratri Day 8: Colour of the day, and Significance
- X to Charge New Users for Engaging with Tweets to Combat Spam
- PM preferred JD(S) leaders more than BJP in Mysuru campaign?
- Celebrating Chaitra Navratri Durga Ashtami 2024: Best Wishes and Messages
- Narendra Modi thanks people of Mangaluru, Dakshina Kannada district
Natco Pharma files ANDA for Bosentan tablets
Drug firm Natco Pharma on Tuesday said it has submitted an abbreviated new drug application (ANDA) with the US health regulator for the generic version of Bosentan 32 mg tablets for oral suspension.
Hyderabad: Drug firm Natco Pharma on Tuesday said it has submitted an abbreviated new drug application (ANDA) with the US health regulator for the generic version of Bosentan 32 mg tablets for oral suspension.
Bosentan 32 mg tablets are sold by Actelion Pharmaceuticals US, Inc under the brand name Tracleer, Natco Pharma said.
The company has filed the ANDA with Para IV certification with the US Food and Drug Administration (USFDA), it added.
"Natco believes that its ANDA is possibly the sole first-to-file based on the filing date. We further believe that our ANDA may be eligible for 180 days of marketing exclusivity at the time of potential launch of the product," the company said.
Tracleer is indicated for treatment of pulmonary arterial hypertension, it added.
